---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-044017"
form_type: "8-K"
ticker: "PRPH"
cik: "0000868278"
company_name: "ProPhase Labs, Inc."
filed_at: "2024-11-07T23:59:59+00:00"
generated_at: "2026-05-30T04:09:29.803052+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# ProPhase Labs proposes public stock offering; discloses $500K term note and future receipts deals

## Summary
- Announced underwritten public offering of common stock and/or pre-funded warrants; no size or price disclosed.
- ThinkEquity sole book-running manager; proceeds earmarked for working capital, product development, and M&A.
- Disclosed $500K term note at 15% interest and two future receipts financings aggregating ~$2.1M.
- BE-Smart esophageal cancer test faces regulatory uncertainty due to new FDA LDT rule.

## SEC filing metadata
- accession: 0001493152-24-044017
- form_type: 8-K
- ticker: PRPH
- cik: 0000868278
- company_name: ProPhase Labs, Inc.
- filed_at: 2024-11-07T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/868278/000149315224044017/0001493152-24-044017-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/868278/000149315224044017/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-044017
- JSON: https://secwatch.observer/filing/0001493152-24-044017.json
- Plain text: https://secwatch.observer/filing/0001493152-24-044017.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.